
Opinion|Videos|April 24, 2024
EMERALD: Elacestrant for ER+/HER2- Advanced Breast Cancer
Dr O’Dea provides an overview of the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer and discusses subgroup analysis data and their clinical implications.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5











































